Page URL:

Predicting patients benefits from new ovarian cancer treatment

23 March 2020
Appeared in BioNews 1040

Analysing the tumour genome and cancer microenvironment can predict an ovarian cancer patient's response to a novel immune-PARP combination treatment, according to a new study.

Previous clinical trials testing a combination of drugs known as immune checkpoint inhibitors and PARP inhibitors can produce strong remissions, leading to complete or partial shrinkage of tumours in 18 percent of patients with so-called 'platinum-resistant ovarian cancer', which is cancer that reappears within six months of completion of multiple-lines of chemotherapy.

There was previously no way to predict which patients would benefit from the experimental treatment in advance. Now, researchers from the Dana-Farber Cancer Institute in Boston, Massachusetts have identified two key factors that are able to predict a beneficial response to a therapeutic approach currently in clinical development for the treatment of patients with advanced ovarian cancer. These two factors are: a DNA repair-related mutation and evidence of involvement of the immune system in the cancer environment.

'By taking these factors into account, researchers leading trials of this combination in patients with advanced, chemotherapy-resistant ovarian cancer may select individuals who may respond to this combination of drugs,' said co-senior author Dr Panagiotis Konstantinopoulos.

The study, published in Nature Communications, characterised tumour samples from 62 individual patients enrolled in a Phase I/II trial of the drug combination.

Comparing immunogenic profiles and imaging data, the authors identified two prognostic features, and discovered that patients whose cancer tissue had one or both of these features were more likely to experience positive effects from the drug combination than those without.

Of the patients with these features, 18 percent had an overall response where the tumour size decreased, including three patients with complete clearance. Furthermore, in 65 percent of patients the drug combination stopped tumour growth, keeping the disease under control.

'Patients with advanced or metastatic ovarian cancer who are resistant to standard platinum-based chemotherapy agents often have few further options for treatment,' Dr Konstantinopoulos commented. 'Our findings will help ensure that patients for whom a PARP inhibitor-checkpoint inhibitor combination won't be beneficial can focus on other clinical trials of treatments that may be more effective for them.'

10 May 2021 - by Emma Bunting 
New research suggests mutations in multiple DNA repair genes can determine how well ovarian cancer patients will respond to the PARP inhibitor, rucaparib...
26 April 2021 - by Hannah Flynn 
Cancer treatment olaparib has been shown to extend the life of relapsed ovarian cancer patients with mutations in BRCA1 and BRCA2, by nearly 13 months, when used as a maintenance therapy...
5 October 2020 - by Dr Melanie Krause 
Women treated for early-stage borderline ovarian tumours may still have a chance of becoming pregnant, according to a new study...
1 June 2020 - by Eleanor Mackle 
Mini versions of mouse reproductive organs have been used to investigate how the most lethal ovarian cancers develop...
24 June 2019 - by Emma Laycock 
Scientists have discovered a set of biomarkers in the blood that could indicate ovarian cancer, which could be used to help diagnose the disease...
29 October 2018 - by Dr Loredana Guglielmi 
A drug to treat ovarian cancer has shown promising results in a clinical trial, delaying signs of relapse and reducing chances of death. The drug olaparib, a PARP inhibitor, was used in patients with BRCA-mutated advanced ovarian cancer...
29 May 2018 - by Martha Henriques 
A virus has been reprogrammed to attack ovarian cancer cells in mice, effectively destroying tumours...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.